Pharmaceutical Company
Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act. Issues generally related to the Orphan Drug Tax Credit, including provisions in H,R. 2623, Camerons Law and H.R. 5376, Build Back Better Act. H.R. 785/S.2313, a bill for the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, and Karla Maria Barrera De Bueso. Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.
HCR - Health Issues MMM - Medicare/Medicaid TAX - Taxation/Internal Revenue Code IMM - Immigration BUD - Budget/Appropriations
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ DEEMA TARAZI ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) DEEMA TARAZI ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ARIEL ALEJANDRO GONZALEZ MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) DEEMA TARAZI ARIEL ALEJANDRO GONZALEZ
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce